While GIP serves as the primary incretin in healthy humans [43], its use as an anti-diabetic agent was initially discouraged by the finding that the insulinotropic action of GIP infusion is severely diminished in patients with T2D [8]. This evidence concerns the gene GCG and type 2 diabetes mellitus.